SRRK
Price:
$27.67
Market Cap:
$2.50B
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients s...[Read more]
Industry
Biotechnology
IPO Date
2018-05-25
Stock Exchange
NASDAQ
Ticker
SRRK
According to Scholar Rock Holding Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -12.46. This represents a change of 131.14% compared to the average of -5.39 of the last 4 quarters.
The mean historical PE Ratio of Scholar Rock Holding Corporation over the last ten years is -10.10. The current -12.46 PE Ratio has changed 12.23% with respect to the historical average. Over the past ten years (40 quarters), SRRK's PE Ratio was at its highest in in the June 2022 quarter at -1.27. The PE Ratio was at its lowest in in the March 2021 quarter at -16.65.
Average
-10.10
Median
-8.38
Minimum
-17.55
Maximum
-4.10
Discovering the peaks and valleys of Scholar Rock Holding Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 140.29%
Maximum Annual PE Ratio = -4.10
Minimum Annual Increase = -60.57%
Minimum Annual PE Ratio = -17.55
Year | PE Ratio | Change |
---|---|---|
2023 | -9.45 | 130.64% |
2022 | -4.10 | -40.77% |
2021 | -6.92 | -60.57% |
2020 | -17.55 | 140.29% |
2019 | -7.30 | 0.18% |
2018 | -7.29 | -34.34% |
2017 | -11.10 | -35.16% |
The current PE Ratio of Scholar Rock Holding Corporation (SRRK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.82
5-year avg
-9.06
10-year avg
-10.10
Scholar Rock Holding Corporation’s PE Ratio is less than TCR2 Therapeutics Inc. (-0.44), greater than Revolution Medicines, Inc. (-17.77), less than Black Diamond Therapeutics, Inc. (-2.05), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.49), less than Monte Rosa Therapeutics, Inc. (-4.83), less than Design Therapeutics, Inc. (-5.95), less than Werewolf Therapeutics, Inc. (-1.83), less than Ikena Oncology, Inc. (-1.24), less than Stoke Therapeutics, Inc. (-7.05), greater than IDEAYA Biosciences, Inc. (-14516.37), less than AnaptysBio, Inc. (-3.21), less than MeiraGTx Holdings plc (-4.12), greater than Keros Therapeutics, Inc. (-12.88), less than Homology Medicines, Inc. (-0.01), greater than Avidity Biosciences, Inc. (-18.98), less than IGM Biosciences, Inc. (-4.30), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), less than Cullinan Oncology, Inc. (-6.16), less than Mineralys Therapeutics, Inc. (-5.57), less than Relay Therapeutics, Inc. (-2.41), less than Pliant Therapeutics, Inc. (-4.72), less than Arvinas, Inc. (-6.26),
Company | PE Ratio | Market cap |
---|---|---|
-0.44 | $58.11M | |
-17.77 | $9.33B | |
-2.05 | $168.95M | |
-0.04 | $3.57M | |
-0.49 | $37.34M | |
-4.83 | $542.54M | |
-5.95 | $301.22M | |
-1.83 | $98.77M | |
-1.24 | $83.00M | |
-7.05 | $689.69M | |
-14516.37 | $2.53B | |
-3.21 | $602.18M | |
-4.12 | $461.30M | |
-12.88 | $2.25B | |
-0.01 | $3.02M | |
-18.98 | $5.25B | |
-4.30 | $930.71M | |
-17.73 | $8.19B | |
-6.16 | $922.99M | |
-5.57 | $671.31M | |
-2.41 | $950.40M | |
-4.72 | $881.01M | |
-6.26 | $1.84B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Scholar Rock Holding Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Scholar Rock Holding Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Scholar Rock Holding Corporation's PE Ratio?
How is the PE Ratio calculated for Scholar Rock Holding Corporation (SRRK)?
What is the highest PE Ratio for Scholar Rock Holding Corporation (SRRK)?
What is the 3-year average PE Ratio for Scholar Rock Holding Corporation (SRRK)?
What is the 5-year average PE Ratio for Scholar Rock Holding Corporation (SRRK)?
How does the current PE Ratio for Scholar Rock Holding Corporation (SRRK) compare to its historical average?